Financials Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:03 2024-07-12 pm EDT 5-day change 1st Jan Change
948.2 USD +1.50% Intraday chart for Eli Lilly and Company +3.67% +62.66%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 853,944 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 874,095 870,063 862,379
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 70.9 x 50.6 x 39.2 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.55% 0.63% 0.71%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 19.9 x 16.2 x 13.7 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 20.3 x 16.5 x 13.8 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 53.8 x 39.2 x 30.3 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 111 x 66.1 x 48.2 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 0.9% 1.51% 2.07%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 46.8 x 28.8 x 19.1 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,405 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 948.4 948.4 948.4
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 42,982 52,793 62,492
EBITDA 1 7,551 8,589 10,005 9,472 8,584 16,238 22,219 28,466
EBIT 1 6,079 7,265 8,457 7,950 7,057 14,699 20,223 25,971
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 34.2% 38.31% 41.56%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 13,749 18,799 22,948
Net income 1 8,318 6,194 5,582 6,245 5,240 11,928 16,677 21,638
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 27.75% 31.59% 34.63%
EPS 2 8.890 6.790 6.120 6.900 5.800 13.37 18.73 24.20
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 7,890 13,159 17,886
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 18.36% 24.93% 28.62%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 48.59% 59.22% 62.83%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 66.15% 78.9% 82.66%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.193 5.993 6.764
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,768 9,998 11,334 12,796 10,920 12,135
EBITDA 1 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 3,049 3,749 4,852 5,984 - -
EBIT 1 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,648 3,077 3,979 4,807 - -
Operating Margin 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 30.2% 30.78% 35.1% 37.56% - -
Earnings before Tax (EBT) 1 - - - - - - 2,089 427.2 2,509 2,536 3,000 3,878 4,496 - -
Net income 1 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,243 2,461 3,256 4,028 - -
Net margin 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 25.58% 24.61% 28.73% 31.48% - -
EPS 2 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.480 2.759 3.610 4.462 - -
Dividend per Share 2 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.300 1.300 1.300 1.299 - -
Announcement Date 2/3/22 4/28/22 8/4/22 11/1/22 2/2/23 4/27/23 8/8/23 11/2/23 2/6/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 20,151 16,119 8,434
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.241 x 0.7254 x 0.2963 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 7,890 13,159 17,886
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 81.9% 73.1% 65.2%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 17.6% 21.3% 24.7%
Assets 1 62,143 42,961 35,816 42,708 56,748 67,652 78,175 87,705
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 20.30 32.90 49.70
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.40 20.00 25.20
Capex 1 1,034 1,388 1,310 1,854 3,448 3,631 3,168 3,289
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 8.45% 6% 5.26%
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4 USD
Average target price
894.8 USD
Spread / Average Target
-5.65%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Financials Eli Lilly and Company